Metabolic Diseases, Overweight, Polycystic Ovary Syndrome
Conditions
Keywords
Abdominal Adipose, Gluteal Adipose, Polycystic Ovary Syndrome, Obesity, Women
Brief summary
The purpose of this study is to collect data to help understand why some women develop Polycystic Ovary Syndrome (PCOS) associated with decreased lower-body fat.
Detailed description
Epigenetics may represent a new regulator mechanism explaining gluteal vs. abdominal fat differences.
Interventions
None listed
Sponsors
Sanford-Burnham Medical Research Institute
Pennington Biomedical Research Center
Boston University
Tufts University
AdventHealth Translational Research Institute
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Female * Age \> 20 and \< 40 * Weight stable (change of less than 3 kg in the last 8 weeks) * BMI \< 40 kg/m2 or \> 27 kg/m2 Supplemental inclusion criteria for PCOS women: * NIH criteria - confirmed by subjects' medical records.
Exclusion criteria
* Male * Women who are pregnant or lactating (breast feeding) * Post-menopausal women * Women with hysterectomy * Diagnosed with diabetes, or have a fasting blood sugar \> 126 mg/dL. * Untreated or symptomatic thyroid disease. * Impaired kidney or liver function, as evidenced by your blood work * Hypertension/ high blood pressure or are taking blood pressure medications * Use of oral contraceptives or hormone replacement therapy. * History of drug or alcohol abuse (\> 3 drinks per day) in the last 5 years, or psychiatric disease prohibiting adherence to study protocol. * History of cancer within the last 5 years. * History of organ transplant. * History of HIV, active Hepatitis B or C, or Tuberculosis. * History of heart attack/ myocardial infarction. * Presence of clinically significant abnormalities on EKG. * Current smokers (smoking within the past 3 months) * Use of any medications known to influence glucose, fat and/or energy metabolism within the last 3 months (e.g., growth hormone therapy, glucocorticoids \[steroids\], etc.). Metformin for women with PCOS is allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference of angiogenesis capacity in abdominal and gluteal adipose tissue | Day 7 | The angiogenesis capacity of each adipose tissue depot will be determine by an in vitro angiogenesis test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of biomarkers in abdominal and gluteal adipose tissue in obese and PCOS women | Day 7 | Measurement will be obtained with Fluorescence-activated cell sorting (FACS). Identify different and similar biomarkers in obese and PCOS women, from abdominal and gluteal adipose tissue samples. Total RNA, micro RNA and DNA will be extracted from each type of cells using FACS-cell sorting analysis. |
| Difference in oxygen content of abdominal and gluteal adipose tissue | Day 6 | Adipose tissue oxygen content will be measured using the Licox CMP microprocessor. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The rates of carbohydrate oxidation | Day -7 | Resting Metabolic Rate (RMR) will measure the resting metabolic rate/respiratory quotient (RMR/RQ) and substrate utilization. Energy expenditure and respiratory quotient standardized for temperature, pressure, and moisture will be calculated at one-minute intervals, over 30 minutes. |
| The rates of lipid oxidation | Day -7 | Resting Metabolic Rate (RMR) will measure the resting metabolic rate/respiratory quotient (RMR/RQ) and substrate utilization. Energy expenditure and respiratory quotient standardized for temperature, pressure, and moisture will be calculated at one-minute intervals, over 30 minutes. |
Countries
United States
Outcome results
None listed